August 18, 2006 – Lilly received an Approvable letter for Arxxant (ark-ZONT), an oral therapy for diabetic retinopathy; Schering-Plough has the right to market golimumab for 15 years, starting from the beginning of sales; a second company is seeking approval of the guaifenesin drug from Adams Respiratory; Monogram Biosciences said four studies showed the importance of its co-receptor tropism assay; EpiCept completed enrolling patients in a Phase III trial of LidoPAIN SP; and a New Jersey court set aside one of Merck’s Vioxx court victories. The Centient Biotech 200™ dropped less than one-tenth of a point to end at 3706.32. More details...
